By Mr. BiotechIll, Guest Author Shares of Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) gain almost half their value after announcement that interim results were presented from its 121 patient randomized, double-blind, placebo-controlled Phase IIb trial in patients with refractory non-small cell lung cancer (NSCLC). At glance: Data show statistically significant improvement in overall survival for patients receiving […]